Genmab

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Genmab and other ETFs, options, and stocks.

About GMAB

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. 

CEO
Jan G. J. van de Winkel
CEOJan G. J. van de Winkel
Employees
3,029
Employees3,029
Headquarters
Copenhagen, Central Denmark
HeadquartersCopenhagen, Central Denmark
Founded
1998
Founded1998
Employees
3,029
Employees3,029

GMAB Key Statistics

Market cap
18.57B
Market cap18.57B
Price-Earnings ratio
18.85
Price-Earnings ratio18.85
Dividend yield
Dividend yield
Average volume
1.99M
Average volume1.99M
High today
$29.26
High today$29.26
Low today
$28.80
Low today$28.80
Open price
$29.15
Open price$29.15
Volume
1.37M
Volume1.37M
52 Week high
$35.43
52 Week high$35.43
52 Week low
$17.24
52 Week low$17.24

Analyst ratings

67%

of 27 ratings
Buy
66.7%
Hold
29.6%
Sell
3.7%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.